Loading clinical trials...
Loading clinical trials...
A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Conditions
Interventions
GeneSight Psychotropic (GEN)
Enhanced-GeneSight Psychotropic (E-GEN)
+1 more
Locations
14
Canada
Chatham-Kent Clinical Trials Research Center
Chatham, Ontario, Canada
Hamilton Community Health Centre Family Health Organization
Hamilton, Ontario, Canada
Hamilton Medical Research Group
Hamilton, Ontario, Canada
St. Joseph's Healthcare Hamilton (SJHH)
Hamilton, Ontario, Canada
Milestone Research
London, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
Start Date
June 1, 2015
Primary Completion Date
November 1, 2018
Completion Date
September 1, 2019
Last Updated
April 30, 2020
NCT07360600
NCT07115329
NCT06793397
NCT07478393
NCT04123314
NCT06906939
Lead Sponsor
Assurex Health Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions